Research Article

Evaluation of a Weight-Based Mycophenolate Mofetil Dosing Protocol for Kidney Transplant Maintenance Immunosuppression

Melanie Tess Mahoney*, Elisabeth Lapp Kincaide, Joelle Nelson, Kelsey Anne Klein, Reed Charles Hall and Suverta Bhayana

Published: 28 July, 2023 | Volume 7 - Issue 2 | Pages: 047-052

To evaluate the safety and efficacy of weight-based mycophenolate mofetil (MMF) dosing in adult kidney transplant recipients (KTR), this single-center retrospective study of adult KTR compared biopsy-proven acute rejection (BPAR), infections, hospitalizations, granulocyte colony-stimulating factor (G-CSF) use, and MMF dose changes within one year of transplant pre-and post-implementation of a weight-based MMF dosing protocol. Adult patients who received a kidney transplant at University Health Transplant Institute were reviewed for inclusion. Patients in the weight-based MMF group received 1000 mg twice daily by the first clinic visit if ≥ 80 kg, 750 mg twice daily if 50-79 kg, and 500 mg twice daily if < 50 kg. Patients in the fixed-dose MMF group received MMF 1000 mg twice daily. A total of 170 KTR (50.0% ≥ 80 kg, 44.1% 50-79 kg, 5.9% < 50 kg) were included. Baseline characteristics were similar between groups. The majority of patients were middle-aged Hispanic males and received lymphocyte-depleting induction therapy. Incidences of BPAR, infection, and hospitalization were similar between both groups at one-year post-transplant. Weight-based MMF dosing is safe and effective in adult KTR.

Read Full Article HTML DOI: 10.29328/journal.jcn.1001108 Cite this Article Read Full Article PDF


  1. Hart A, Lentine K, Smith J. OPTN/SRTR 2019 Annual Data Report: Kidney. 2019: 105.
  2. Genentech USA. Cellcept (mycophenolate mofetil): Highlights of Prescribing Information. San Francisco, CA. 1995.
  3. Kahu J, Kyllönen L, Salmela K. Impact of mycophenolate mofetil intolerance on early results of kidney transplantation. Transplant Proc. 2005 Oct;37(8):3276-9. doi: 10.1016/j.transproceed.2005.09.014. PMID: 16298571.
  4. Squifflet JP, Bäckman L, Claesson K, Dietl KH, Ekberg H, Forsythe JL, Kunzendorf U, Heemann U, Land W, Morales JM, Mühlbacher F, Talbot D, Taube D, Tyden G, van Hooff J, Schleibner S, Vanrenterghem Y; European Tacrolimus-MMF Renal Study Group. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation. 2001 Jul 15;72(1):63-9. doi: 10.1097/00007890-200107150-00014. PMID: 11468536.
  5. Kim H, Yi NJ, Lee J, Kim J, Moon MR, Jeong J, Lee JM, You TS, Suh SW, Park MS, Choi Y, Hong G, Lee HW, Lee KW, Suh KS. Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation. Clin Mol Hepatol. 2014 Sep;20(3):291-9. doi: 10.3350/cmh.2014.20.3.291. Epub 2014 Sep 25. PMID: 25320733; PMCID: PMC4197178.
  6. Yau WP, Vathsala A, Lou HX, Chan E. Is a standard fixed dose of mycophenolate mofetil ideal for all patients? Nephrol Dial Transplant. 2007 Dec;22(12):3638-45. doi: 10.1093/ndt/gfm468. Epub 2007 Jul 19. PMID: 17640939.
  7. Oellerich M, Shipkova M, Schütz E, Wieland E, Weber L, Tönshoff B, Armstrong VW. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit. 2000 Feb;22(1):20-6. doi: 10.1097/00007691-200002000-00004. Erratum in: Ther Drug Monit 2000 Aug;22(4):500. PMID: 10688252.
  8. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable Ther Drug Monit. 2001 Aug;23(4):305-15. doi: 10.1097/00007691-200108000-00001. PMID: 11477311.
  9. Kuypers DR, Le Meur Y, Cantarovich M, Tredger MJ, Tett SE, Cattaneo D, Tönshoff B, Holt DW, Chapman J, Gelder Tv; Transplantation Society (TTS) Consensus Group on TDM of MPA. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010 Feb;5(2):341-58. doi: 10.2215/CJN.07111009. Epub 2010 Jan 7. PMID: 20056756.
  10. Yamada S, Shiohira H, Uehara H, Hokama N, Saitou S, Ooshiro Y. Implications of Clinical Mycophenolate Mofetil Dose According to Individual Body Weight in Japanese Renal Transplant Recipients. Transplant Proc. 2016 Jan-Feb;48(1):35-41. doi: 10.1016/j.transproceed.2015.11.014. PMID: 26915840.
  11. Khosroshahi HT, Shoja MM, Peyrovifar A, Hashemi SR, Amjadi M. Mycophenolate mofetil dose reduction in renal transplant recipients: a 5-year follow-up study. Transplant Proc. 2009 Sep;41(7):2797-9. doi: 10.1016/j.transproceed.2009.07.036. PMID: 19765438.
  12. Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009 Jul;9(7):1607-19. doi: 10.1111/j.1600-6143.2009.02668.x. Epub 2009 May 20. PMID: 19459794.
  13. Yarlagadda SG, Coca SG, Garg AX, Doshi M, Poggio E, Marcus RJ, Parikh CR. Marked variation in the definition and diagnosis of delayed graft function: a systematic review. Nephrol Dial Transplant. 2008 Sep;23(9):2995-3003. doi: 10.1093/ndt/gfn158. Epub 2008 Apr 11. PMID: 18408075; PMCID: PMC2727302.
  14. Al-Bahou AA, Webb AR, Bloxam M, Anger LJBowman, Baliga RS, Brueckner AJ. Outcomes Associated with Mycophenolate Weight-Based Dosing in Varying Immunologic Risk Kidney Transplant Recipients. Am J Transplant. 2020; 20 (suppl 3).
  15. Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol. 2003 Sep;14(9):2381-6. doi: 10.1097/01.asn.0000079616.71891.f5. PMID: 12937317.
  16. Dave V, Polkinghorne KR, Leong KG, Kanellis J, Mulley WR. Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function. Sci Rep. 2020 Nov 9;10(1):19379. doi: 10.1038/s41598-020-76379-6. PMID: 33168923; PMCID: PMC7653942.
  17. Yarlagadda SG, Coca SG, Formica RN Jr, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant. 2009 Mar;24(3):1039-47. doi: 10.1093/ndt/gfn667. Epub 2008 Dec 22. PMID: 19103734.
  18. Humar A, Johnson EM, Payne WD, Wrenshall L, Sutherland DE, Najarian JS, Gillingham KJ, Matas AJ. Effect of initial slow graft function on renal allograft rejection and survival. Clin Transplant. 1997 Dec;11(6):623-7. PMID: 9408697.
  19. Rodrigo E, Fernández-Fresnedo G, Ruiz JC, Piñera C, Palomar R, González-Cotorruelo J, Zubimendi JA, De Francisco AL, Sanz de Castro S, Arias M. Similar impact of slow and delayed graft function on renal allograft outcome and function. Transplant Proc. 2005 Apr;37(3):1431-2. doi: 10.1016/j.transproceed.2005.02.052. PMID: 15866627.
  20. Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35. doi: 10.2165/00003495-200363240-00009. PMID: 14664658.
  21. Taber DJ, Egede LE, Baliga PK. Outcome disparities between African Americans and Caucasians in contemporary kidney transplant recipients. Am J Surg. 2017 Apr;213(4):666-672. doi: 10.1016/j.amjsurg.2016.11.024. Epub 2016 Nov 18. PMID: 27887677; PMCID: PMC5373991.
  22. Heilman RL, Reddy KS, Mazur MJ, Moss AA, Post DJ, Petrides S, Mulligan DC. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Transplant Proc. 2006 Jun;38(5):1307-13. doi: 10.1016/j.transproceed.2006.02.116. PMID: 16797289.
  23. Woodle ES, Alloway RR, Buell JF, Alexander JW, Munda R, Roy-Chaudhury P, First MR, Cardi M, Trofe J. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant. 2005 Nov;5(11):2740-4. doi: 10.1111/j.1600-6143.2005.01090.x. PMID: 16212635.
  24. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1996 Apr 15;61(7):1029-37. PMID: 8623181.
  25. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet. 1995 May 27;345(8961):1321-5. PMID: 7752752.
  26. Vanhove T, Kuypers D, Claes KJ, Evenepoel P, Meijers B, Naesens M, Vanrenterghem Y, Cornelis T, Bammens B. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. Transpl Int. 2013 Aug;26(8):813-21. doi: 10.1111/tri.12133. Epub 2013 Jun 10. PMID: 23746202.


Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?